Glycadia, Inc. is a clinical stage biopharmaceutical company developing therapeutics for the prevention and treatment of kidney, eye and cardiovascular diseases that result from diabetes.

The company’s lead product, GLY-230, is entering Phase IIb clinical trials in diabetic nephropathy.

Products for additional indications are expected to enter clinical trials next year.

Diabetes and its associated complications have reached epidemic proportions. 

The current medical approach to forestalling diabetic complications concentrates on improving blood glucose levels and decreasing HbA1c. Despite “optimal” management with insulin and/or oral hypoglycemic agents and the advent of new anti-diabetic therapies, more than 70% of patients remain out of glycemic control.

There are no drugs currently available on the market that directly target diabetes-specific abnormalities underlying the microvascular and macrovascular complications of this disease. Glycadia's product pipeline addresses this under-served medical need.